Gilead agreed to pay Kymera Therapeutics $45 million to exercise an option on a preclinical anticancer molecular glue degrader, adding another oncology asset to a pipeline built through dealmaking. The transaction reflects continued investor and partner emphasis on molecular-glue modalities as a route to new target coverage. The added program comes as Gilead pursues portfolio expansion through multiple acquisitions and partnerships, positioning new oncology mechanisms alongside its existing franchises in cancer and immunology. Industry participants will track follow-on milestones and the degrader’s ability to translate from preclinical activity into differentiated clinical profiles, particularly in biomarker-defined settings.